BMEA Biomea Fusion Inc

DURABLE GLYCEMIC CONTROL WITH BMF-219 DURING OFF-TREATMENT PERIOD AT WEEK 26: Exhibit 99.2 A PHASE 1/2 TRIAL OF BMF-219 IN PATIENTS WITH TYPE 2 DIABETES (COVALENT-111) 1 2 3 4 5 6 7 7 7 7 7 7 Jose Rodriguez , Alexander Abitbol , Douglas Denham , Rizwana Mohseni , Janice Faulknor , Cesar Perez , Brian Munneke , Courtney Follit , Juan Frias , Sanchita Mourya , Thomas Butler , Steve Morris ; 1 2 3 4 5 6 South West General Healthcare Center, FL, United States of America, LCM Clinical Research, Canada, Clinical Trials of Texas, TX, United States of America, Catalina Research Institute, CA, United States of America, BioPharma Services, Canada, Sunbright Health Medical Center, Clinical Trial Investigator, FL, 7 United States of America, Biomea Fusion, CA, United States of America Background Glycemic Results Summary at Week 26 (22 Weeks After Last Dose of BMF-219) Case Study BMF-219 100mg BMF-219 200mg BMF-219 100mg BMF-219 200mg • T2D is characterized by hyperglycemia due to a progressive decline in beta- Placebo • 51-year-old man with 5-year history of T2D • BMF-219 100mg QD without food for 4 weeks Without Food Without Food With Food With Food N = 6 • Metformin 500mg BID • Metformin continued N = 10 N = 9 N = 10 N = 2 cell function 2 • HbA 8.9%; FPG 184mg/dL; BMI 32.1 kg/m • No adverse events reported 1c Mean change in HbA1c -0.5% -0.1% 0.1% -1.1% 0.3% • Menin, a scaffold protein, is an important regulator of glycemic control, Placebo Adjusted Mean -0.8% -0.4% -0.2% -1.4% -- Change in HbA1c by Study Week CGM Across Study Visits whereby inhibition of menin enhances beta cell proliferation and function Change in HbA1c Percent of Participants with • BMF-219 is an oral covalent menin inhibitor in clinical development for the ≥ 1.0 reduction in HbA1c at 2/10 (20%) 2/9 (22%) 2/10 (20%) 2/2 (100%) 0/6 (0%) Week 26 management of T2D and T1D • In preclinical diabetes ZDF and STZ rat models, BMF-219 showed durable Increase in HOMA-B and C-Peptide at Week 26 1,2 glycemic control following short-term treatment % Change in HOMA-B % Change in C-Peptide • In multiple ascending dose (MAD) cohorts in patients with T2D, 4 weeks of .0 (100mg and 200mg cohorts combined) (100mg and 200mg cohorts combined) BMF-219 100 and 200mg once daily dosing improved glycemic control at Responders* Non-responders Responders* Non-responders 3 Week 26 (22 weeks after the final dose) Aim Week 12 Week 26 Week 4 Baseline Week 12 Week 26 A case study demonstrating continued improvement in HbA1C and improved Time In Range on CGM (after • To assess the safety and efficacy of 4 weeks of once daily BMF-219 at completion of 4 weeks of once daily oral treatment), indicating a durable glycemic control. Week 26 (22 weeks after final dose) Summary and Conclusion Methods • At Week 26 (22 weeks after completion of a 4-week regimen) 100 and 200 mg • COVALENT-111 (NCT05731544) is an ongoing Phase 1/2 randomized, double- N = 8 N = 3 N = 3 N = 17 BMF-219 resulted in: blind, placebo controlled, MAD study evaluating BMF-219 in patients with N = 8 N = 3 inadequately controlled T2D who receive once-daily BMF-219 (50, 100, 200, • Durable glycemic response (≥1.0% HbA1C reduction in 20% and 36% of N = 18 N = 3 patients in once daily 100 and 200mg cohorts, respectively) 400mg) for 4 weeks and are followed until Week 26. • Key eligibility criteria: Adults with T2D treated with up to 3 antidiabetic • Durable increase in C-peptide at Week 26 (22 weeks off treatment) for Placebo Placebo Active Placebo Active Active Active Placebo agents (excluding SU, insulin), HbA1c 7%-10.5%, T2D duration ≤ 15 years BMF-219 responders After 4 weeks of once-daily dosing, responders across both 100 and 200mg cohorts had a greater increase in HOMA-B and • Primary endpoint: Safety and tolerability • Patients who demonstrated the greatest HbA1c reduction at Week 26, had C-peptide AUC when compared to non-responders and placebo. • Secondary endpoints: Measures of glycemic control (HbA1c, CGM), beta cell * Responders have baseline HOMA-B <200 and have achieved at least 0.5% decrease in HbA1c at Week 26 greatest improvement in beta cell function as measured by HOMA-B and function (HOMA-B and C-peptide), and durability of glycemic response C-peptide 200mg Cohorts (N=11) 200mg Cohorts (N=11) Study Design • A generally well tolerated safety profile with no serious adverse events Day 1 BMF-219 Week 4 and no adverse event-related study discontinuations Week 26 (100mg or 200 mg) Daily • No symptomatic or clinically significant hypoglycemia Dosing Period Off-Treatment Period • Robust durable responses seen in many patients after 4 weeks of BMF-219 and Baseline Characteristics and Demographics the demonstration of improvement in beta-cell function which correlates with 100mg without 200mg without 100mg with 200mg with Placebo this glycemic response, support the assessment of longer duration of therapy 1 Characteristics Food Food Food Food (8-12 weeks) with BMF-219 N = 10 N = 10 N = 10 N = 2 N = 6 Age (yrs) 52 (38,63) 50 (25,64) 51 (35,60) 61 (60,61) 46 (31,61) • Subsequent study cohorts are currently assessing BMF-219 administration for Female 4 (40%) 4 (40%) 3 (30%) 2 (100%) 0 (0%) Male 6 (60%) 6 (60%) 7 (70%) 0 (0%) 6 (100%) N = 6 N = 4 N = 3 N = 3 N = 5 N = 6 N = 5 N = 4 up to 12 weeks, with follow-up until Week 52 Duration of diabetes (yrs) 4.3 (0.3,9.3) 4.9 (0.5,11.7) 8.3 (2.6,13.6) 11.3 (9.7,12.8) 3.9 (0.7,9.5) Baseline HbA1c (%) 8.1 (0.92) 7.85 (0.82) 7.96 (0.62) 8.35 (0.64) 8.25 (0.71) Any Decrease in Any Decrease At least 0.5% At least 0.5% Any Decrease in Any Decrease in At least 0.5% At least 0.5% Baseline therapy HbA1c in HbA1c and decrease in Decrease and HbA1c HbA1c and decrease in Decrease and References Baseline HbA1c Baseline Baseline HbA1c Baseline Metformin only 9 (90%) 6 (60%) 5 (50%) 0 (0%) 5 (83%) HOMA-B* <200 HOMA-B* <200 HOMA-B* <200 HOMA-B* <200 Other 1 (10%) 2 (20%) 4 (40%) 2 (100%) 1 (17%) 1. Butler T. et al. Oral Long-Acting Menin Inhibitor Normalizes Type 2 Diabetes Mellitus (T2DM) in Two Rat Models. Diabetes 1 June 2022; 71 (Supplement_1): 851–P. 2. Somanath P. et al. Oral Menin Inhibitor, BMF-219, Displays a Significant and Durable Reduction in HbA1c in a Type 2 Diabetes Mellitus Rat Model. Diabetes 1 June 2022; None 0 (0%) 2 (20%) 1 (10%) 0 (0%) 0 (0%) HOMA-B and C-peptide at Week 26 increases with magnitude of reduction in HbA1C and in patients with baseline HOMA-B <200 71 (Supplement_1): 113–LB. 1 with BMF-219 200 mg once daily dosing for 4 weeks. Mean (Minimum, Maximum); n (%); Mean (SD) 3. Frias J. et al. BMF-219: A Novel Therapeutic Agent to Re-Establish Functional Beta Cells and Provide Long-Term Glycemic Control. Metabolism May 2023; 142 (Supplement): Abstract#0088 * HOMA-B <200 is considered beta cell deficient Mean % Change in HOMA-B Mean % Change in HOMA-B Mean % Change in C-Peptide AUC Mean % Change in C-Peptide AUC Change in HbA1c (%) % Time in Glucose Range

KEY OBSERVATIONS FROM THE DOSE-ESCALATION PORTION OF COVALENT-111, A PHASE 1/2 Exhibit 99.3 TRIAL OF THE COVALENT MENIN INHIBITOR BMF-219 IN PATIENTS WITH TYPE 2 DIABETES 1 2 3 4 5 6 7 7 7 7 7 7 Alexander Abitbol , Jose Rodriguez , Douglas Denham , Rizwana Mohseni , Janice Faulknor , Cesar Perez , Courtney Follit , Brian Munneke , Steve Morris , Sanchita Mourya , Thomas Butler , Juan Frias ; 1 2 3 4 5 6 LCM Clinical Research, Canada, South West General Healthcare Center, FL, United States of America, Clinical Trials of Texas, TX, United States of America, Catalina Research Institute, CA, United States of America, BioPharma Services, Canada, Sunbright Health Medical Center, Clinical Trial Investigator, FL, 7 United States of America, Biomea Fusion, CA, United States of America Case Study Background Results • T2D is characterized by hyperglycemia due to a progressive decline in beta- Across initial cohorts (n=31; 100 and 200mg with or without food), 39% of • 61-year-old woman with 10-year history of T2D • BMF-219 200 mg QD with food for 4 weeks • Metformin 500 mg BID; liraglutide 1.2mg QD (GLP-1 cell function • Metformin, liraglutide (GLP-1 RA), and canagliflozin patients had a ≥0.5% HbA1c reduction at Week 26. Importantly, with higher RA); canagliflozin 500 mg QD (SGLT2i) (SGLT2i) continued • Menin, a scaffold protein, is as an important regulator of glycemic control, BMF-219 exposure observed in the 200mg with food cohort, patients (n=2) 2 • HbA 7.9%; FPG 163 mg/dL; BMI 29.4 kg/m • No serious adverse events reported 1c whereby inhibition of menin enhances beta-cell proliferation and function diagnosed >7 years and failing dual- or triple-agent therapy at baseline (including Change in HbA1c by Study Week CGM Across Study Visits • BMF-219 is an oral covalent menin inhibitor in clinical development for the GLP1 RA and/or SGLT2i) had a robust HbA1c response to BMF-219 (-0.5%, -1.1%, management of T2D and T1D and -1.1% at Weeks 4, 12, and 26, respectively). • In diabetes ZDF and STZ rat models, BMF-219 showed durable glycemic 1,2 PK at Week 4 and Corresponding HbA1c Response at Week 26 control following 2-4 weeks of treatment • In multiple ascending dose (MAD) cohorts in patients with T2D, 4 weeks of PK Response Across Cohorts HbA1c Response (Week 26*) BMF-219 100 and 200mg once daily improved glycemic control at Week 26 3 (22 weeks after the final dose) 1000 N = 6 N = 9 N = 10 0.0 N = 10 N = 9 N = 9 N = 2 • Here we present key observations from COVALENT-111, a trial assessing BMF-219 in patients with T2D 750 -0.5 Week 4 Week 12 Week 26 Baseline Week 12 Week 26 Aim 500 A patient with a 10-year history of T2D and on triple-agent regimen (metformin, GLP1 RA, and SGLT2i) at • To assess the safety and efficacy of daily BMF-219 treatment for 4 weeks at baseline, experienced a 1.1% reduction in HbA1c and an increase of 30% in TIR compared to baseline at Week 26 -1.0 Week 26 (22 weeks after final dose) 250 Summary and Conclusions N = 8 N = 10 N = 8 N = 8 N = 2 N = 9 0 Methods At Week 26 (22 weeks after completion of 4 weeks of treatment): 50mg 100mg with 100mg 200mg 100mg 200mg PBO 50mg 100mg 100mg 200mg 100mg 200mg food BID with food with food BID with • Patients in COVALENT-111 are displaying improved glycemic control while off • In COVALENT-111, adults with T2D received BMF-219 daily (with or without food therapy, supporting improved pancreatic function following BMF-219 treatment food) for 4 weeks in multiple ascending dose cohorts (50, 100, 200, 400 mg) (Left) Dose-dependent PK response among 100 and 200mg cohorts with the 200mg dose taken with food • A higher proportion of patients treated with 200mg QD achieved a clinically resulting in the highest PK exposure with follow-up until Week 26 significant reduction in HbA1c compared to 100mg QD dosing (Right) HbA1c response across cohorts at Week 26* (22 weeks after final BMF-219 dose), suggesting durability • Key eligibility: Adults with T2D treated with up to 3 antidiabetic agents of response • A durable glycemic response (≥1.0% HbA1C reduction) was seen in 20% and 36% (excluding SU and insulin), HbA1c 7%-10.5%, T2D duration ≤15 years of patients in once daily 100 mg and 200 mg cohorts, respectively *Data depicted for 50mg cohort reflects Week 20 values, the most recent timepoint for which information is available • Primary endpoint: Safety and tolerability • Across 100mg QD, 200mg QD, and 100mg BID cohorts (N=40), 38% of patients Proportion of Patients with ≥1% HbA1c Reduction at Week 26 • Secondary endpoints: Measures of glycemic control (HbA1c, CGM), beta-cell had ≥0.5% HbA1c reduction with a mean HbA1c reduction of 1.2%, and 23% of function (HOMA-B and C-peptide), and durability of glycemic response Response Rate, 100mg and 200mg patients had ≥1.0% HbA1c reduction with a mean HbA1c reduction of 1.5% at • 20% of patients across 100mg QD Week 26 Study Design cohorts and 36% patients across 200 • Patients with >7 years duration of diabetes and failing dual- or triple-agent mg QD cohorts demonstrated ≥1.0% BMF-219 Day 1 Week 4 therapy (including GLP1 RA and/or SGLT2i) also demonstrated improved Week 26 (100mg or 200 mg) Daily HbA1c reduction at Week 26 (22 glycemic control (HbA1c -0.4%, -1.1%, and -1.1% at Weeks 4, 12, and 26, weeks after the final dose). Dosing Period Off-Treatment Period respectively) with BMF-219 200mg with food • Across 100 and 200mg cohorts 50mg QD* • A generally well tolerated safety profile with no SAEs was observed (N=31), 39% of patients had ≥0.5% 100mg QD • These data demonstrate the novel disease-modifying potential of short-term HbA1c reduction at Week 26, with 200mg QD a mean HbA1c reduction of 1.3%. BMF-219 therapy in patients with T2D 100mg BID • Across 100 and 200mg cohorts • The expansion phase of COVALENT-111 aims to further optimize long-term glycemic 200/400mg QD (N=31), 26% of patients had ≥1.0% 100mg QD control, dosing BMF-219 for up to 12 weeks with follow-up until Week 52 HbA1c reduction at Week 26, with a 200mg QD References mean HbA1c reduction of 1.5%. 4 Weeks Dosing 22-Week Follow-Up 200mg QD 1. Butler T. et al. Oral Long-Acting Menin Inhibitor Normalizes Type 2 Diabetes Mellitus (T2DM) in Two Rat Models. Diabetes 1 June 2022; 71 (Supplement_1): 851–P. Placebo 100mg QD 2. Somanath P. et al. Oral Menin Inhibitor, BMF-219, Displays a Significant and Durable Reduction in HbA1c in a Type 2 Diabetes Mellitus Rat Model. Diabetes 1 June 2022; 71 (Supplement_1): 113–LB. 3. Frias J. et al. BMF-219: A Novel Therapeutic Agent to Re-Establish Functional Beta Cells and Provide Long-Term Glycemic Control. Metabolism May 2023; 142 (Supplement): Abstract #0088 *Open-label with no placebo Food Without Food Mean AUC (ng*hr/ml) Response Rate (%) last Mean Change in HbA1c (%) Change in HbA1c (%) % Time in Glucose Range

CASE STUDIES FROM COVALENT-111, A PHASE 1/2 TRIAL OF BMF-219, A COVALENT MENIN Exhibit 99.4 INHIBITOR, IN PATIENTS WITH TYPE 2 DIABETES 1 2 3 4 5 6 7 7 7 7 7 7 Douglas Denham , Alexander Abitbol , Rizwana Mohseni , Jose Rodriguez , Cesar Perez , Janice Faulknor , Courtney Follit , Brian Munneke , Steve Morris , Juan Frias , Thomas Butler , Sanchita Mourya ; 1 2 3 4 5 Clinical Trials of Texas, TX, United States of America, LCM Clinical Research, Canada, Catalina Research Institute, CA, United States of America, South West General Healthcare Center, FL, United States of America, Sunbright Health Medical Center, Clinical Trial Investigator, FL, United States of America, 6 7 BioPharma Services, Canada, Biomea Fusion, CA, United States of America Background Results • T2D is characterized by hyperglycemia due to a gradual decline in beta-cell Case Study 1 Case Study 2 function • 29-year-old man with 4-year history of T2D• BMF-219 200 mg QD without food for 4 weeks• BMF-219 100 mg QD with food for 4 weeks • 45-year-old man with 10-year history of T2D • Menin, a scaffold protein, is as an important regulator of glycemic control, • Metformin 500 mg BID, empagliflozin 25 mg BID• Metformin and SGLT2i continued • Metformin 500 mg BID• Metformin continued 2 • No adverse events reported 2 whereby inhibition of menin enhances beta cell proliferation and function• HbA 9.5%; FPG 134 mg/dL; BMI 25.6 kg/m• No adverse events reported 1c • HbA 8.6%; FPG 235 mg/dL; BMI 29.6 kg/m 1c • At (Week 26), HbA1c 7.0% (change from baseline [CFB], • CGM TIR 34% • CGM TIR 4%• At (Week 26), HbA1c 7.5% (CFB, -1.1%), FPG 144 • BMF-219 is an oral covalent menin inhibitor in clinical development for the -2.2%), FPG 105 mg/dL (CFB, -24 mg/dL), TIR 90% (CFB, mg/dL (CFB, -91 mg/dL), TIR 79% (CFB, +73%), HOMA +65%). B (CFB, 12-fold increase). management of T2D and T1D • In preclinical diabetes ZDF and STZ rat models, BMF-219 showed durable Change in HbA1c by Study Week CGM Across Study Visits Change in HbA1c by Study Week CGM Across Study Visits 1,2 glycemic control following short-term treatment • In a multiple ascending dose (MAD) cohorts in patients with T2D, 4 weeks of BMF-219 100 and 200mg once daily dosing improved glycemic control at 3 Week 26 and was generally safe and well tolerated • Here, we highlight two BMF-219-treated T2D patients who demonstrated significant efficacy in a double blind randomized-controlled trial Aim • To assess the safety and efficacy of BMF-219 once daily treatment for 4 Week 4 Week 12 Week 26 Week 4 Week 12 Week 26 Baseline Week 12 Week 20 Baseline Week 12 Week 26 weeks at Week 26 (22 weeks after final dose) % Change HOMA-B at Week 26 % Change C-Peptide at Week 26 % Change HOMA-B at Week 26 % Change C-Peptide at Week 26 Methods • In COVALENT-111, adults with T2D receiving up to 3 antidiabetic agents received BMF-219 with or without food once daily for 4 weeks in MAD cohorts (50, 100, 200, and 400mg), with follow-up until Week 26 • Key eligibility criteria: Adults with T2D treated with up to 3 antidiabetic agents (excluding insulin secretagogues and insulin), HbA1c 7%-10.5%, diabetes duration ≤15 years • Primary endpoint: Safety and tolerability • Secondary endpoints: Measures of glycemic control (HbA1c, CGM), beta cell function (HOMA-B and C-peptide), and durability of glycemic response At Week 26, a 45-year-old male participant with 10-year history of T2D experienced a 1.1% reduction in HbA1c and an At Week 26, a 29-year-old male participant with a 4-year history of T2D experienced a 2.5% reduction in HbA1c and an increase of 75% TIR compared to baseline after 4 weeks BMF-219 100mg QD with food, indicating a durable effect on Study Design increase of 56% TIR compared to baseline after 4 weeks BMF-219 200mg QD without food, indicating a durable effect glycemic control. on glycemic control. BMF-219 Day 1 Week 4 Week 26 (100mg or 200 mg) Daily Summary and Conclusions References Dosing Period Off-Treatment Period 50mg QD* 1. Butler T. et al. Oral Long-Acting Menin Inhibitor Normalizes Type 2 Diabetes Mellitus • These case studies illustrate the potential disease-modifying and durable effect 100mg QD (T2DM) in Two Rat Models. Diabetes 1 June 2022; 71 (Supplement_1): 851–P. of short-term BMF-219 treatment in patients with uncontrolled T2D 200mg QD 2. Somanath P. et al. Oral Menin Inhibitor, BMF-219, Displays a Significant and Durable 100mg BID • HbA1c and Time-In-Range (TIR) on CGM continue to improve while off treatment Reduction in HbA1c in a Type 2 Diabetes Mellitus Rat Model. Diabetes 1 June 2022; 200/400mg QD 71 (Supplement_1): 113–LB. 100mg QD • Increase in HOMA-B and C-peptide correlates with glycemic control, consistent 200mg QD 3. Frias J. et al. BMF-219: A Novel Therapeutic Agent to Re-Establish Functional Beta with BMF-219's core mechanism of action: beta-cell proliferation and improved Cells and Provide Long-Term Glycemic Control. Metabolism May 2023; 142 beta-cell function 4 Weeks Dosing 22-Week Follow-Up (Supplement): Abstract #0088 *Open-label with no placebo Food Without Food Change in HbA1c (%) % Time in Glucose Range Change in HbA1c (%) % Time in Glucose Range

Biomea Fusion (NASDAQ:BMEA)
Historical Stock Chart
From Mar 2024 to Apr 2024

Biomea Fusion (NASDAQ:BMEA)
Historical Stock Chart
From Apr 2023 to Apr 2024